Treatment Trends and Cost Associated With Peyronie's Disease
Introduction: Providers may use several treatment options for patients with Peyronie's disease; however, it is unclear whether practice patterns have evolved over recent years and if this has impacted cost. Aims: To investigate trends in the treatment of Peyronie's disease over time and th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2020-12-01
|
| Series: | Sexual Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2050116120301124 |
| _version_ | 1827846616817598464 |
|---|---|
| author | Christopher J. Loftus, MD Saneal Rajanahally, MD Sarah K. Holt, PhD Omer A. Raheem, MD Kevin A. Ostrowski, MD Thomas J. Walsh, MD, MS |
| author_facet | Christopher J. Loftus, MD Saneal Rajanahally, MD Sarah K. Holt, PhD Omer A. Raheem, MD Kevin A. Ostrowski, MD Thomas J. Walsh, MD, MS |
| author_sort | Christopher J. Loftus, MD |
| collection | DOAJ |
| description | Introduction: Providers may use several treatment options for patients with Peyronie's disease; however, it is unclear whether practice patterns have evolved over recent years and if this has impacted cost. Aims: To investigate trends in the treatment of Peyronie's disease over time and the associated costs using a national, commercial insurance claims database. Methods: A retrospective cohort study was conducted using claims from the Truven MarketScan database from 2007 to 2018 for men with Peyronie's disease. Cost was estimated as either the sum of prescription oral or injectable treatment costs or as the single net cost associated with the operative procedure. Main Outcome Measures: Frequency of use of various treatments for Peyronie's disease and associated costs were assessed as trends over the timeline by year. Results: The estimated annual incidence of Peyronie's disease in this population rose from 61 to 77 per 100,000 patients over the included years, and the percent annual treatment rate rose from 17.8% to 26.2%. Colchicine was the most commonly prescribed oral agent in 2007 used in 22% of treated individuals; by 2018, pentoxifylline was the most common prescribed oral agent used in 33%. In 2007, 11% of treated patients received intralesional verapamil; however, by 2018, 24% received injectable collagenase, whereas <1% received intralesional verapamil. The mean annual, per-individual cost of Peyronie's disease treatment increased from $1,531 in 2007 to $10,339 in 2018. The cost increase was greatest for injectable therapies, which rose from $811 per individual in 2007 to $16,184 in 2018, a 19-fold increase. Conclusions: Diagnosis and treatment of Peyronie's disease is increasing over time. Pentoxifylline has become the most common oral prescription, whereas injectable collagenase has become most common injection. The mean cost associated with Peyronie's disease treatment increased more than 5 times from 2007 to 2018 corresponding with Federal Drug Administration's approval of injectable collagenase.Loftus CJ, Rajanahally S, Holt SK, et al. Treatment Trends and Cost Associated With Peyronie's Disease. Sex Med 2020;8:673–678. |
| first_indexed | 2024-03-12T09:18:35Z |
| format | Article |
| id | doaj.art-f32e4e9db107431dabb6e829122f0bb4 |
| institution | Directory Open Access Journal |
| issn | 2050-1161 |
| language | English |
| last_indexed | 2024-03-12T09:18:35Z |
| publishDate | 2020-12-01 |
| publisher | Oxford University Press |
| record_format | Article |
| series | Sexual Medicine |
| spelling | doaj.art-f32e4e9db107431dabb6e829122f0bb42023-09-02T14:41:30ZengOxford University PressSexual Medicine2050-11612020-12-0184673678Treatment Trends and Cost Associated With Peyronie's DiseaseChristopher J. Loftus, MD0Saneal Rajanahally, MD1Sarah K. Holt, PhD2Omer A. Raheem, MD3Kevin A. Ostrowski, MD4Thomas J. Walsh, MD, MS5Department of Urology, University of Washington Medical Center, Seattle, WA; Corresponding Author: Christopher J. Loftus, MD, Department of Urology, University of Washington Medical Center, 1959 NE Pacific St, Box 356510, Seattle, WA 98195, USA. Tel: 206-685-1982; Fax: 206-543-3272Department of Urology, Baylor College of Medicine, Houston, TXDepartment of Urology, University of Washington Medical Center, Seattle, WADepartment of Urology, Tulane University School of Medicine, New Orleans, LADepartment of Urology, University of Washington Medical Center, Seattle, WADepartment of Urology, University of Washington Medical Center, Seattle, WAIntroduction: Providers may use several treatment options for patients with Peyronie's disease; however, it is unclear whether practice patterns have evolved over recent years and if this has impacted cost. Aims: To investigate trends in the treatment of Peyronie's disease over time and the associated costs using a national, commercial insurance claims database. Methods: A retrospective cohort study was conducted using claims from the Truven MarketScan database from 2007 to 2018 for men with Peyronie's disease. Cost was estimated as either the sum of prescription oral or injectable treatment costs or as the single net cost associated with the operative procedure. Main Outcome Measures: Frequency of use of various treatments for Peyronie's disease and associated costs were assessed as trends over the timeline by year. Results: The estimated annual incidence of Peyronie's disease in this population rose from 61 to 77 per 100,000 patients over the included years, and the percent annual treatment rate rose from 17.8% to 26.2%. Colchicine was the most commonly prescribed oral agent in 2007 used in 22% of treated individuals; by 2018, pentoxifylline was the most common prescribed oral agent used in 33%. In 2007, 11% of treated patients received intralesional verapamil; however, by 2018, 24% received injectable collagenase, whereas <1% received intralesional verapamil. The mean annual, per-individual cost of Peyronie's disease treatment increased from $1,531 in 2007 to $10,339 in 2018. The cost increase was greatest for injectable therapies, which rose from $811 per individual in 2007 to $16,184 in 2018, a 19-fold increase. Conclusions: Diagnosis and treatment of Peyronie's disease is increasing over time. Pentoxifylline has become the most common oral prescription, whereas injectable collagenase has become most common injection. The mean cost associated with Peyronie's disease treatment increased more than 5 times from 2007 to 2018 corresponding with Federal Drug Administration's approval of injectable collagenase.Loftus CJ, Rajanahally S, Holt SK, et al. Treatment Trends and Cost Associated With Peyronie's Disease. Sex Med 2020;8:673–678.http://www.sciencedirect.com/science/article/pii/S2050116120301124Healthcare TrendsInjectable CollagenasePeyronie's DiseaseCost of Treatment |
| spellingShingle | Christopher J. Loftus, MD Saneal Rajanahally, MD Sarah K. Holt, PhD Omer A. Raheem, MD Kevin A. Ostrowski, MD Thomas J. Walsh, MD, MS Treatment Trends and Cost Associated With Peyronie's Disease Sexual Medicine Healthcare Trends Injectable Collagenase Peyronie's Disease Cost of Treatment |
| title | Treatment Trends and Cost Associated With Peyronie's Disease |
| title_full | Treatment Trends and Cost Associated With Peyronie's Disease |
| title_fullStr | Treatment Trends and Cost Associated With Peyronie's Disease |
| title_full_unstemmed | Treatment Trends and Cost Associated With Peyronie's Disease |
| title_short | Treatment Trends and Cost Associated With Peyronie's Disease |
| title_sort | treatment trends and cost associated with peyronie s disease |
| topic | Healthcare Trends Injectable Collagenase Peyronie's Disease Cost of Treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2050116120301124 |
| work_keys_str_mv | AT christopherjloftusmd treatmenttrendsandcostassociatedwithpeyroniesdisease AT sanealrajanahallymd treatmenttrendsandcostassociatedwithpeyroniesdisease AT sarahkholtphd treatmenttrendsandcostassociatedwithpeyroniesdisease AT omeraraheemmd treatmenttrendsandcostassociatedwithpeyroniesdisease AT kevinaostrowskimd treatmenttrendsandcostassociatedwithpeyroniesdisease AT thomasjwalshmdms treatmenttrendsandcostassociatedwithpeyroniesdisease |